faculty portrait if available
Seetharama Jois
Professor
Basic Pharmaceutical Sciences
PHAR 316
318-342-1993
ULM logo

Seetharama D Jois, PhD
Professor, Pharmacy

Education

Ph D

1994,
Indian Institute of Science, Bangalore, India

MS

1986, Solid State Physics
University of Mysore, India

BS

1984, Physics, Chemistry, Mathematics
University of Mysore, India

faculty feature photo

Biographical Sketch

Dr. Seetharama D. Jois is a professor of Medicinal Chemistry in the school of Pharmacy, the University of Louisiana at Monroe, USA. Before joining the University of Louisiana at Monroe in 2006, he worked as an Assistant Professor in the school of Pharmacy at the National University of Singapore for six years. Dr. Jois obtained his Ph.D. degree in 1994 from Molecular Biophysics Unit, Indian Institute of Science (IISc), Banglore, India and a Master’s degree in Physics from the University of Mysore India. After his Ph.D. degree, Dr. Jois obtained extensive training in Pharmaceutical Chemistry research at the University of Kansas in Lawrence, KS. During the past 11 years at ULM, he has established research in a unique area of drug design discovery, namely protein-protein interaction and drug design. Dr. Jois’ research interest is in the area of peptidomimetic based drug design as a promising approach for developing therapeutic agents for autoimmune diseases, inflammatory diseases, and cancer. Dr. Jois has published more than 80 original papers and 70 abstracts, and he has edited a book, Drug Design and Discovery (Humana Press, 2011) and two special issue journals. Recently, he has applied for a provisional and a PCT patent application. In addition to research work, Dr. Jois is involved in teaching Medicinal Chemistry and protein biochemistry to professional Pharm.D students and computational and experimental methods of drug discovery to graduate students.

Licensure & Certification

Education Scholar an “online course certification in Developing a Personal Working Philosophy of Teaching/Learning in Health., online course. (February 15 2010 - Present)

Research Interests

Protein-protein interactions play an important role in a wide range of physiological and pathological processes. The interaction between the proteins involves small surface binding epitopes. Thus, protein-protein interactions can be modulated by blocking surface epitopes of proteins. Hence, inhibition of protein-protein interaction has a tremendous impact on understanding the structural basis of these interactions and in developing new therapeutic strategies for many human diseases. Our group is focusing on two important areas of research to tweak the protein-protein interactions.

1. Design and structural studies of peptides for cell-adhesion inhibition

The main research interest is in the area of modulation of protein-protein interactions involved in cell-cell adhesion by peptides and peptidomimetics. Modulation of cell adhesion is essential for suppression of the immune response in autoimmune diseases, improving drug delivery through the biological barriers (i.e., intestinal mucosa and blood-brain barriers) and inhibition of tumor metastasis. The design of inhibitors of these interactions and their structural studies is the main goal of the research program. The current research focus is on the design of peptides and peptidomimetics from CD2 protein to disrupt the interaction of CD2 and CD58 (also called LFA3) protein molecules. For the past 12 years, I have designed peptides and peptidomimetics in this particular area. Preliminary in vivo studies using an animal model, collagen-induced arthritis in mice (CIA), indicated that a peptide from CD2 was able to suppress rheumatoid arthritis in mice. Furthermore, with the help of a collaborator, we have shown that these peptides are also effective in modulating the immune response in T cells that are derived from transgenic mice that develop arthritis similar to human arthritis. At present I am working on grafting these peptides to cyclotides, which are plant-derived peptides that have a multicyclic structure with disulfide bonds, are resistant to thermal, chemical, and enzymatic degradation, and are orally bioavailable.


2. Design of small molecular inhibitors targeted towards HER-2 as therapeutic agents for breast and lung cancer.

Growth factors are important mediators of cell proliferation. The interaction of growth factors with their receptors generates signal transduction. The intracellular domains of these receptor proteins are protein tyrosine kinases. The overexpression or activation of these receptors results in uncontrolled cell proliferation. Epidermal growth factor receptor (EGFR) kinase and the related Human Epidermal Growth Factor Receptor-2 (HER-2) are the growth factors that have implications in cancer. The overexpression or activation of HER-2 frequently occurs in breast, ovarian and lung cancers. HER-2 oncogene in human breast carcinomas has been associated with a more aggressive course of the disease. The protein HER2 is known to interact with other EGFRs and form dimers/heteromers. The blockade of protein-protein interactions of HER2 with other EGFRs ultimately leads to control of cell growth and, hence, has therapeutic value for lung cancer patients. Using the three-dimensional structure of HER2 protein and its interaction with other receptors, I have designed novel peptidomimetics that target the extracellular domain of human epidermal growth factor receptor -2 (HER2) and inhibit the dimerization of HER2 with other receptors such as HER2: HER3 and EGFR: HER2. This approach is novel because the peptidomimetic molecule designed disrupts not only EGFR-HER2 dimerization but also HER2-HER3 dimerization. This project is funded by National Cancer Institute (NCI), National Institute of Health (NIH) grant number 1R15CA188225-01A1.

Recent Publications

Pallerla, S., Naik, H., Singh, S., Gauthiier, T., Sable, R., Jois, S. (2018). Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. J Pept Sci..
Singh, S. (2017). Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. Advances in Protein Chemistry and Structural Biology.
Kanthala, S. P., Liu, Y., Singh, S., Sable, R., Pallerla, S. (2017). A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization (pp. 74244-74262). Oncotarget.
Sable, R., Parajuli, P., Jois, S. (2017). Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications (pp. E124). Marine Drugs.
Zhao, N., Williams, T., Zhou, Z., Fronczek, F., Sibrian-Vazquez, M., Jois, S., Vicente, G. M. (2017). Synthesis of BODIPY-Peptide Conjugates for Fluorescence Labeling of EGFR over-expressing Cells (pp. 1566-1579). Bioconjug Chem.
Pallerla, S., Gauthier, T., Sable, R., Jois, S. (2017). Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. (pp. 914-924). Eur. J. Med. Chem..
Sable, R., Durek, T., Taneja, V., Craik, D., Pallerla, S., Jois, S. (2016). Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein interaction (pp. 2366-2374). ACS Chemical Biology.
Gokhale, A., Sable, R., Walker, J. D., McLaughlin, L., Kousoulas, K. G., Jois, S. (2015). Inhibition of cell adhesion and immune responses in the mouse model of collagen-induced arthritis with a peptidomimetic that blocks CD2-CD58 interface interactions. (pp. 733-742). Biopolymers.
David, L., Gokhale, A., Jois, S., Behrens, M., Luthra, H., Taneja, V. (2016). CD74/DQA1 dimers predispose to the development of arthritis in humanized mice. (pp. 204-211). Immunology.
Fontenot, K., Ongarora, B., LeBlanc, L. E., Zhou, Z., Jois, S., Vicente, G. M. (2016). Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates. (pp. 352-366). Journal of Porphyrins and Phthalocyanines.
Kanthala, S. P., Mill, C., Riese, D., Jaiswal, M., Jois, S. (2015). Expression and purification of HER2 extracellular domain protein in Schneider2 Insect cells. (pp. 26-33). West Monroe: Protein Expr Purif..
Sable, R., Jois, S. (2015). Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors (pp. 11569-11603.). Molecules.
Samy, R. P., Thwin, M. M., Stiles, B. G., Satyanarayanajois, S., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., Siveen, K. S., Sikka, S., Kumar, A. P., Sethi, G., Lim, L. H. (2015). Novel phospholipase A2 inhibitors from python serum are potent peptide antibiotics (pp. 30-44). Biochimie.
Shanthi, K. P., Pallerla, S., Jois, S. D. (2015). Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors (pp. 865-878). Future Oncol.
Kanthala, S., Banappagari, S., Ameya, G., Gu, X., Zhao, Y., Liu, Y., Jois, S. (2014). Novel Peptidomimetics For Inhibition of HER2:HER3 Heterodimerization in HER2 Positive Breast Cancer (pp. 702-714). Chem. Biol. Drug Des.
Perumal, S., Kone, G., Stiles, B., Satyanarayanajois, S., Chow, V. (2014). Snake venom proteins and peptides as novel antibiotics against microbial infections (pp. 1-15). Current Proteomics.
Gokhale, A., Jois, S. (2014). Peptides and peptidomimetics as immunomodulators. (pp. 755-774). Immunotherapy.
Kanthala, S., Gauthier, T., Jois, S. (2014). Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. (pp. :693-702). Biopolymers.
Banappagari, S., McCall, A., Fontenot, K., Vicente, G., Satyanarayanajois, S. (2013). Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain (pp. 60-69). Monroe: Eur. J. Med. Chem.
Lakshminarayanan, R., Vivekanandan, S., Samy, R. P., Banerjee, Y., Chi-Jin, E. O., Teo, K. W., Satyanarayana-Jois, S., Kini, R. M., Valiyaveettil, S. (2008). Structure, self-assembly, and dual role of a beta-defensin-like peptide from the Chinese soft-shelled turtle eggshell matrix (pp. 4660-4668). Journal of the American Chemical Society/American Chemical Society.
Giddu, S., Subramanian, V., Yoon, H., Satyanarayana-Jois, S. (2009). Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. (pp. 726-736). ACS Publishers: Journal of medicinal Chemistry.
Satyanarayana-Jois, S., Villalba, S., Jianchao, L., Mei Lin, G. (2009). Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines (pp. 246-257). Chemical Biology and Drug Design.
Maung, T. M., Satyanarayana-Jois, S., Gopalakrishnakone, P. (2010). Venom neutralization by purified bioactive molecules: Synthetic peptide derivatives of the endogenous PLA(2) inhibitory protein PIP. Toxicon.
Satyanarayana-Jois, S. (2010). A Peptide from Beta-strand Region of CD2 Protein that Inhibits Cell-adhesion Suppresses Arthritis in a Mouse Model (pp. 234-244). Chemical Biology and Drug Design.
Satyanarayana-Jois, S. (2010). Active-Learning Exercises to Teach Drug-Receptor Interactions in a Medicinal Chemistry Course (pp. 147). American Journal of Pharmaceutical Education.
Sashikanth, B., Sharon, R., Satyanarayana-Jois, S. (2010). A Conformationally Constrained Peptidomimetic Binds to Extracellular Region of HER2 Protein (pp. 289-308). Adenine Press NY: Journal of Biomolecular Structure and Dynamics.
Satyanarayana-Jois, S. (2011). Heterotypic Cell Adhesion Assay For the Study of Cell Adhesion Inhibition (pp. Chapter 14, 225-243). NY: Methods in Molecular Biology Protocols.
Satyanarayana-Jois, S. (2011). Drug Design and Discovery-Methods and Protocols (pp. 284 pages). NY: Humana Press.
Banappagari, S., Ronald, S., Satyanarayana-Jois, S. (2011). Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines (pp. 752-759. DOI: 10.1039/C1MD00126D). RSC Publications: Medicinal Chemistry Communication.
Gokhale, A. S., Weldeghiorghis, T., Satyanarayana-Jois, S., Taneja, V. (2011). Conformationally Constrained Peptides from CD2 to Modulate Protein-Protein Interactions between CD2 and CD58 (pp. 5307–5319). Columbus OH: American Chemical Scoiety.
Satyanarayana-Jois, S., Hill, R. (2011). Medicinal chemistry for 2020 (pp. 1765-1786). Future Medicinal Chemistry.
Satyanarayana-Jois, S., Hill, R. A. (2011). Medicinal chemistry for 2020 (pp. 1765-1786). Future Medicinal Chemistry/Future Science Group.
Fontenot, K., Ongarora, B., Hu, X., Hollingsworth, J., Seghal, I., Satyanarayana-Jois, S., Vicente, G. (2012). Syntheses and Biological Properties of Phthalocyanine-EGFR Peptide Conjugates (pp. 3725-3738). American Chemical Society, Columbus OH: Journal of Medicinal Chemistry.
Banappagari, S., Satyanarayana-Jois, S., Corti, M., Pincus, S. (2012). Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. (pp. 594-606). Albany, NY Adenine Press: Journal of Biomolecular Structure and Dynamics.
Alayoubi, A., Satyanarayana-Jois, S., Sylvester, P. W., Nazzal, S. (2012). Multisimplex Optimization of Tocotrienol-Rich Self Emulsified Drug Delivery Systems (pp. 153-161). International Journal of Pharmaceutics.
Satyanarayana-Jois, S. (2013). Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain (pp. 60-69). Europe/Elsevier: European Journal of Medicinal Chemistry.
Gokhale, A., Kanthala, S., Taneja, V., Satyanarayana-Jois, S. (2013). Immunosuppression by Co-stimulatory Molecules: Inhibition of CD2-CD48/CD58 Interaction by Peptides from CD2 to Suppress Progression of Collagen-induced Arthritis in Mice. (pp. 106-118). Chemical Biology and Drug Design/Wiley.
Alayoubi, A., Kanthala, S., Satyanarayana-Jois, S., Anderson, J. F., Sylvester, P. W., Nazzal, S. (2013). Stability and in vitro antiproliferative activity of bioactive “Vitamin E” fortified parenteral lipid emulsions (pp. 23-30). Colloids and Surfaces B: Biointerfaces.
Alayoubi, A., Anderson, J. F., Satyanarayana-Jois, S., Sylvester, P. W., Nazzal, S. (2013). Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells (pp. 385-392). European Journal of Pharmaceutical Sciences.

Research Grants

Jois, S. D. (Principal), "Molecular mechanism of EGFR heterodimerization: inhibition by a peptidomimetic" (Funded), Sponsored By NCI/NIH, External to The University of Louisiana at Monroe, $394,376. (September 01 2015 - August 31 2018).
Jois, S. (Co-Principal), Vicente, G. (Principal), "CRC-specific near-IR agents for tumor imaging" (Awarded, Not Yet Funded), Sponsored By NIH LSU-subaward, External to The University of Louisiana at Monroe, $200,204. (August 1 2014 - July 30 2018).
Jois, S. D. (Principal), "Establishment of peptide and protein facility at ULM" (Funded), Sponsored By Louisiana Board of Regents, External to The University of Louisiana at Monroe, $76,429. (June 01 2016 - June 30 2017).
Jois, S. (Principal), "Biomolecules derived from plants as an inspiration for designing drug-like molecules for therapeutic purposes." (Funded), Sponsored By Louisiana Campuses Research Initiative, External to The University of Louisiana at Monroe, $30,000. (July 01 2015 - June 30 2016).
Satyanarayana-Jois, S. (Principal), "Role of domain IV of HER2 protein in cell signaling" (Funded), Sponsored By NIH-LSU Subcontract, External to The University of Louisiana at Monroe, $500000. (May 1 2011 - April 30 2015).
Satyanarayana-Jois, S. (Principal), "Role of CD2 peptides for Immunomodulation" (Funded), Sponsored By Louisiana BOR, External to The University of Louisiana at Monroe, $102000. (June 1 2009 - May 30 2012).
El Sayed, K. (Principal), Hill, R. A. (Co-Principal), Briski, K. (Co-Principal), Meyer, S. (Co-Principal), Khalil, A. (Co-Principal), Akins, R. L. (Co-Principal), Satyanarayana-Jois, S. (Co-Principal), "Enhancement of ULM College of Pharmacy NMR Spectrometery" (Pending Funding Decision), Sponsored By Louisiana BoR-TRADITIONAL ENH Program, External to The University of Louisiana at Monroe, $159785. (June 01 2010 - June 30 2011).
Satyanarayana-Jois, S., "Synthesis and characterization of conjugates of peptidomimetics with fluorescent labels and europium chelators for the study of ligand-receptor interactions." (Funded), Sponsored By La-EPSCoR Pfund (NSF), $10000. (January 2010 - December 2010).
Satyanarayana-Jois, S. (Principal), Shah, G. (Supporting), El Sayed, K. (Supporting), Nazzal, S. (Supporting), Liu, Y. (Supporting), Hussain, A. (Supporting), "Circular Dichroism Spectropolarimeter for Enhancing Pharmaceutical Research" (Funded), Sponsored By Louisiana BOR, External to The University of Louisiana at Monroe, $. (June 1 2009 - May 30 2010).
Satyanarayana-Jois, S., Vicente, G. (Other), "Targeting HER2 protein for breast cancer usign computational approach" (Funded), Sponsored By LBRN/INBRE (NIH), External to The University of Louisiana at Monroe, $55000. (May 1 2009 - April 30 2010).
Satyanarayana-Jois, S. (Principal), Vicenete, G. M. (Other), "Targeting HER2 protein for breast cancer using computational approach" (Funded), Sponsored By Louisiana Biomedical Research (LBRN/INBRE), The University of Louisiana at Monroe, $50000. (September 01 2008 - April 30 2009).
Satyanarayana-Jois, S. (Principal), Hammer, R. P. (Other), "Targeting HER2 protein for breast cancer" (), Sponsored By Louisiana Biomedical Research (LBRN/INBRE) NIH, External to The University of Louisiana at Monroe, $50000. (January 2 2008 - August 31 2008).

Awards & Honors

July 2017 AACP Teacher of the year.

May 2017 Excellence in teaching.

August 2016 ULM Foundation Awards for Excellence in Research.

July 2009 AACP teacher of the year.

May 2009 Teaching Excellence Award.

May 2008 Teaching Excellence Award.

May 2004 Visiting Professor, University of Arizona, Tucson, Arizona USA.

March 2003 JSPS fellowship.

Courses Taught

PHAR 4007Medicinal Chemistry I, 3 course(s)

PHAR 4018Chemotherapeutic Agts, 1 course(s)

PHAR 5000MOLEC STRUC/FUNC PROTEIN, 3 course(s)

PHRD 4002PRINCIPLES OF DRUG ACTION I, 6 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 6 course(s)

PHRD 4058NEUROLOGY & PSYCHIATRY MODULE, 2 course(s)

PHRD 4081INFECTIOUS DISEASES MODULE, 7 course(s)

PHRD 4083GASTRO NUTRITION & HEPTIC MOD, 2 course(s)

PHRD 5010CARDIOVASCULAR MODULE, 5 course(s)

PHRD 5027BONE AND JOINT MODULE, 4 course(s)

PHRD 5033RENAL/UROLOGY MODULE, 4 course(s)

PHRD 5035HEMATOLOGY/ONCOLOGY MODULE, 6 course(s)